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Abstract
Background: G protein-coupled receptors (GPCRs) interact with heterotrimeric GTP-binding
proteins (G proteins) to modulate acute changes in intracellular messenger levels and ion channel
activity. In contrast, long-term changes in cellular growth, proliferation and differentiation are often
mediated by tyrosine kinase receptors and certain GPCRs by activation of mitogen-activated
protein (MAP) kinases. Complex interactions occur between these signaling pathways, but the
specific mechanisms of such regulatory events are not well-understood. In particular it is not clear
whether GPCRs are modulated by tyrosine kinase receptor-MAP kinase pathways.
Results: Here we describe tyrosine kinase receptor regulation of a GPCR via MAP kinase. Insulin
reduced the activity of the 5-HT2C receptor in choroid plexus cells which was blocked by the MAP
kinase kinase (MEK) inhibitor, PD 098059. We demonstrate that the inhibitory effect of insulin and
insulin-like growth factor type 1 (IGF-1) on the 5-HT2C receptor is dependent on tyrosine kinase,
RAS and MAP kinase. The effect may be receptor-specific: insulin had no effect on another GPCR
that shares the same G protein signaling pathway as the 5-HT2C receptor. This effect is also direct:
activated MAP kinase mimicked the effect of insulin, and removing a putative MAP kinase site from
the 5-HT2C receptor abolished the effect of insulin.
Conclusion: These results show that insulin signaling can inhibit 5-HT2C receptor activity and
suggest that MAP kinase may play a direct role in regulating the function of a specific GPCR.
Background
It was originally thought that GPCRs and tyrosine kinase
receptors functioned independently to mediate different
signaling events, but it has become clear in recent years
that some functions and signaling pathways are shared
(for reviews, see Marinissen and Gutkind, 2001 [1]; Lut-
trell, 2002 [2]; and van Biesen et al., 1996 [3]). For exam-
ple, some classical neurotransmitters such as 5-HT have
short-term effects on ion channels and other effectors
such as adenylyl cyclase but also have growth factor-like
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fibroblasts (reviewed in Gerhardt and van Heerikhuizen,
1997 [5]). The peptide hormones insulin and IGF-1 have
both short-term metabolic effects and long-term actions
on cell growth and differentiation. Insulin and IGF-I bind
and stimulate tyrosine kinase receptors which interact
with a large number of effectors [6,7]. Complex interac-
tions occur between these two types of signaling pathways
that are the subject of intense investigation.
The 5-HT2C receptor displays a heterogeneous distribution
in the CNS [8] and is not found in peripheral tissues. It is
abundant in choroid plexus where it modulates the pro-
duction of cerebrospinal fluid (CSF), and in limbic
regions and hypothalamus where it may play a role in
motor behavior and appetite control. The 5-HT2C receptor
has been implicated in anxiety, migraine, movement dis-
orders, eating disorders and neuroendocrine regulation
[9]. The importance of the 5-HT2C receptor in regulation
of food intake is evident in a knockout mouse developed
by Tecott et al. [10]. The obesity found in these mice is due
to excessive food intake and this phenotype along with
increased plasma levels of insulin and leptin is analogous
to Type 2 diabetes. The knockout mouse is also suscepti-
ble to epileptic-like seizures – suggesting that the 5-HT2C
receptor has a role in tonic inhibition of neuronal
excitability.
5-HT2C receptors and insulin/IGF-1 receptors share some
functional roles; both have trophic effects in the brain and
modulate appetite. 5-HT2C receptors [8] and insulin/IGF-
1 receptors [11] co-localize in several areas in the brain
including choroid plexus, olfactory bulb, cerebral cortex,
hypothalamus, and hippocampus. Interactions between
insulin and serotonergic pathways may have important
consequences for their known roles in appetite modula-
tion and trophic actions in the brain. We chose to look for
these types of interactions in choroid plexus because both
5-HT2C receptors and insulin/IGF-1 receptors are abun-
dant in this tissue and because the 5-HT2C receptor is the
only 5-HT receptor present in these cells.
The 5-HT2C receptor is a member of the GPCR family.
GPCRs stimulate heterotrimeric G proteins which release
activated Gα and Gβγ subunits to interact with a variety of
effectors. The function of GPCRs is tightly regulated by
phosphorylation by second messenger activated kinases
(protein kinase A and protein kinase C) and G protein-
coupled receptor-specific kinases (GRKs). Arrestins bind
phosphorylated receptors and further down-regulate
receptor activity by inhibiting G protein interaction. It is
well-known that GPCRs can regulate the activity of tyro-
sine kinase/MAP kinase pathways. However, there is little
evidence for reciprocal regulation: MAP kinase effects on
GPCR function. Here we report such evidence – insulin-
mediated MAP kinase regulation of 5-HT2C receptor
activity.
Results
Effect of insulin signaling on 5HT2C receptor function in 
choroid plexus cells
We examined the effects of insulin signaling on 5-HT2C
receptor function in isolated rat choroid plexus cells. Acti-
vation of 5-HT2Creceptors in choroid plexus stimulates
phosphoinositol hydrolysis [12] and increases intracellu-
lar calcium [13]. We measured changes in intracellular
calcium in response to serotonin (5-HT) with the calcium
indicator, fura. A robust increase in intracellular calcium
was seen in response to 5-HT (Fig. 1a and 1c) and this
response could be completely blocked with the selective
5-HT2C receptor antagonist, mesulergine (data not
shown). The response to 5-HT was significantly attenu-
ated (40% inhibition) when choroid plexus cells were
treated with insulin before superfusing serotonin (Fig. 1b
and 1c). Pretreatment with PD 098059, a MEK inhibitor
blocked the inhibitory effect of insulin (Fig. 1c) but had
no effect on the serotonin response when used alone.
These data indicate that insulin inhibits 5-HT2C receptor
activity and MEK is an obligatory component of insulin's
action, implicating the involvement of the MAP kinase
pathway.
Characterization of the mechanism of insulin's effect on 
5HT2C receptor function in Xenopus oocytes
To delineate the mechanism of insulin's action on the 5-
HT2C receptor, we used the Xenopus oocyte expression sys-
tem. Oocytes contain endogenous insulin and IGF-1
receptors [14]. They also have many of the proteins in the
RAS and MAP kinase pathways, which have been impli-
cated in cell cycle control and re-entry into meiosis
[15,16].. We expressed two GPCRs, a serotonin receptor
(5-HT2C) and an M1 muscarinic acetylcholine (Ach)
receptor. Both receptors utilize G proteins for signaling;
they stimulate phosphoinositide hydrolysis and increased
phospholipase C activity which leads to transient activa-
tion of a Ca2+-dependent Cl- current in the oocytes. Acti-
vation of either receptor can cross-desensitize the other,
suggesting that they share the same G protein pathway.
To determine the effect of insulin receptor or IGF-1 recep-
tor activation on GPCR's, cells were treated with insulin or
IGF-1. The Cl- currents elicited by subsequent 5-HT or Ach
stimulation were compared with those without insulin/
IGF-1 treatment. As shown in Fig. 2, treatment with insu-
lin or IGF-1 resulted in a significant reduction of the peak
Cl- current in response to 5-HT, but did not affect the
response to Ach. Insulin alone did not induce an ionic
current under these conditions (data not shown). Insulin
treatment did not affect the general characteristics of the
Cl- current induced by 5-HT or Ach, i.e., a depolarizingPage 2 of 9
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phase (Figs. 2a and 2b, top). Instead, insulin specifically
reduced the peak Cl- current in response to 5-HT by 83%
compared to untreated controls (1513 ± 138 nA vs. 261 ±
78 nA, Fig. 2a, middle) with no change in the magnitude
of the Cl- current in response to Ach (2681 ± 281 nA vs.
2785 ± 186 nA, Fig. 2b, middle). Similar to the effect of
insulin, IGF-1 treatment specifically reduced the magni-
tude of the Cl- current in response to 5-HT by 56% (1665
± 222 nA vs. 737 ± 181 nA, Fig. 2a, bottom), without
affecting the response to Ach (1275 ± 272 nA vs. 1220 ±
243, Fig. 2b, bottom). These data indicate that the inhibi-
tory effect of insulin/IGF-1 is specific for the 5-HT2C recep-
tor.
Insulin and IGF-1 receptors activate several different regu-
latory proteins, including RAS, MAP kinase, PI3 kinase, S6
kinase and protein tyrosine phosphatase [6,7,17]. Initia-
tion of this transduction cascade requires the intrinsic
tyrosine kinase activity of the insulin/IGF-1 receptors. To
determine whether or not tyrosine kinase activity was
required for the action of insulin/IGF-1, the tyrosine
kinase inhibitor genistein was used. As shown in Fig. 3a,
in oocytes pretreated with genistein before IGF-1 admin-
istration, the reduction in 5-HT-induced Cl- current was
abolished, whereas genistein treatment alone had no
effect on the 5-HT response in oocytes not treated with
IGF-1.
The insulin/IGF-1 pathway diverges into RAS-dependent
and -independent paths. To identify which path is
involved, an anti-RAS antibody that can neutralize RAS
activity was injected into oocytes before IGF-1 treatment.
This RAS antibody (Y13-259) has been shown in oocytes
to block the re-entry into meiosis or germinal vesicle
breakdown induced by IGF-1 [18]. Antibody injection
blocked the effect of IGF-1 on the 5-HT response (Fig. 3b),
demonstrating that the inhibitory effect of insulin/IGF-1
was RAS-dependent.
RAS activates a cascade of kinases, including RAF, MAP
kinase kinase (MEK) and MAP kinase. The involvement of
this pathway in regulation of 5-HT receptor function was
examined. Pretreating cells with PD 098059, a specific
MEK kinase inhibitor [19], blocked the effect of IGF-1 on
the 5-HT response, whereas inhibition of protein kinase C
did not (Fig. 4a). These results suggest that MEK is
involved in mediating the inhibitory effect of the insulin/
IGF-1 pathway.
MEK's primary role is activation of MAP kinase through
threonine and tyrosine phosphorylation of MAP kinase
which in turn phosphorylates and regulates the function
of several nuclear proteins, such as transcription factors,
as well as cytosolic and membrane-associated proteins,
such as the insulin and EGF receptors. To determine
whether MAP kinase is involved in mediating the insulin/
IGF-1 effect, activated MAP kinase [20] was injected into
oocytes before testing the 5-HT response. Active MAP
kinase reduced the 5-HT response by 56% compared to
untreated controls (Fig. 4b), demonstrating that active
MAP kinase is capable of mimicking the inhibitory effect
of insulin/IGF-1 on the 5-HT2C receptor.
The 5-HT2C receptor contains a putative MAP kinase site
[21] at serine 159 in the second intracellular loop between
the 3rd and 4th transmembrane domains. To ascertain
whether MAP kinase directly modulates the receptor func-
tion, this amino acid was changed to alanine by site-
directed mutagenesis. As shown in Fig. 4c, insulin no
Figure 1
Effect of insulin and PD 098059 on the response to 
serotonin in rat choroid plexus cells. (A) Change in 
intracellular calcium in response to 5-HT in a representative 
choroid plexus cell. Horizontal bar above the trace indicates 
bath application of 2 µM 5-HT. (B) Change in intracellular 
calcium in response to 5-HT after 10 minute treatment with 
insulin in a representative choroid plexus cell. Horizontal 
bars above the trace indicate bath application of 10 µM insu-
lin or 2 µM 5-HT. (C) Change in peak intracellular calcium 
concentration in response to 5-HT with and without insulin 
treatment and/or PD 098059 pretreatment. Basal intracellu-
lar calcium levels averaged 20-50 nM for all groups. The data 
are presented as mean ± S.E.M. * indicates a statistical differ-
ence (P < 0.05) of the insulin treatment group when com-
pared to control.Page 3 of 9
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mutant receptor S159A, indicating that serine 159 is likely
the site of MAP kinase modulation.
Discussion
The 5-HT2C receptor is a member of the G protein-coupled
receptor superfamily and one of over 30 cloned serotonin
receptors. Except for the 5-HT3 receptor which is an oligo-
meric ion channel, all serotonin receptors are GPCRs and
are divided into seven subfamilies based on sequence
homology, gene structure, and signaling pathways
[22,23]. The 5-HT2C receptor, like other members of the 5-
HT2 family, stimulates phospholipase C, and increases IP3
and DAG which leads to increased intracellular calcium
and mediates many cellular processes. In general 5-HT2
receptor types are growth-regulatory and stimulate cell
Figure 2
Effect of insulin and IGF-1 on the peak Cl- current in response to serotonin or acetylcholine in Xenopus oocytes 
expressing 5-HT2C and M1 acetylcholine receptors. (A) Effects of insulin or IGF-1 on the peak Cl- current in response to 
5-HT. Top left, representative Cl- current trace after stimulation with 5-HT. Top right, representative Cl- current trace after 
stimulation with 5-HT in an oocyte pre-treated with insulin. Horizontal bars above the current traces indicate bath application 
of 1 µM 5-HT. Middle, effects of insulin on the peak Cl- current induced by 5-HT. Bottom, effects of IGF-1 on the peak Cl- cur-
rent induced by 5-HT. (B) Effects of insulin or IGF-1 on the peak Cl- current in response to Ach. Top left, representative cur-
rent trace after stimulation with Ach. Top right, representative current trace after stimulation with Ach in an oocyte previously 
treated with insulin. Horizontal bars above the current traces indicate bath application of 10 µM Ach. Middle, effects of insulin 
on the peak Cl- current induced by Ach. Bottom, effects of IGF-1 on the peak Cl- current induced by Ach. The data are pre-
sented as mean ± S.E.M. of 12-16 oocytes (*, P < 0.05).Page 4 of 9
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[25] receptors, the 5-HT2C receptor is not known to
activate MAP kinase. The 5-HT2C receptor activates multi-
ple signal transduction cascades in vivo and in heterolo-
gous expression systems (see Raymond et al 2001 [22];
and Gerhardt and van Heerikhuizen, 1997 ([5], for
reviews). In choroid plexus, the 5-HT2C receptor stimu-
lates PI turnover, increases cGMP formation and activates
Cl- channels. In heterologous expression systems, the 5-
HT2C receptor can couple to two different K+ channels [26]
and in some cases either activation or inactivation of ade-
nylyl cyclase has been demonstrated in addition to the
well-known activation of phospholipase C and PI
turnover.
The regulation of the 5-HT2C receptor has been the focus
of several studies, but the results have been difficult to
interpret for several reasons including the complex
pharmacology of this receptor. The presence of spare 5-
HT2C receptors [27] in choroid plexus has also compli-
cated the study of desensitization in vivo. However, it has
been demonstrated that denervation of 5-HT neurons
supersensitizes 5-HT2C receptors [28] in choroid plexus,
suggesting that these receptors are under tonic control by
5-HT. In primary cultures of choroid plexus cells, repeated
5-HT application desensitizes 5-HT induced increases in
intracellular calcium [13]. Down-regulation of receptor
binding sites in choroid plexus cells is seen after agonist
treatment [29]. However, inverse agonists can either
down- [29] or up-regulate [30] 5-HT2C receptor binding
sites dependent upon cellular context. The mechanisms
Figure 3
Effects of tyrosine kinase inhibitor and dominant-
negative RAS antibody on IGF-1 effects on the serot-
onin response in Xenopus oocytes. Shown are peak Cl- 
currents in response to 5-HT after the indicated treatments. 
(A) Genistein, a tyrosine kinase inhibitor, blocks the inhibi-
tory effect of IGF-1 on the 5-HT response. The data are pre-
sented as mean ± S.E.M. of 11-12 oocytes (*, P < 0.05). (B) 
RAS antibody, Y13-259, blocks the inhibitory effect of IGF-1 
on the 5-HT response. The data are presented as mean ± 
S.E.M. of 6 oocytes (*, P < 0.05).
Figure 4
Role of MAP kinase in the inhibitory effect of IGF-1 
on the 5-HT response in Xenopus oocytes. Plotted are 
peak Cl- currents in response to 5-HT after the indicated 
treatments. (A) The MEK kinase inhibitor, PD 098059, but 
not the protein kinase C inhibitor (PKC I), blocks the inhibi-
tory effect of IGF-1 on the 5-HT response. The data are pre-
sented as the mean ± S.E.M. of 6 oocytes (*, P < 0.05).  (B)  
Activated MAP kinase mimics the IGF-1 inhibitory effect on 
the 5-HT response. The data are presented as the mean ± 
S.E.M. of 8-12 oocytes (*, P < 0.05).  (C) Mutation of the 
putative MAP kinase site on the 5-HT2C receptor abolishes 
the insulin effect.  In oocytes expressing the wild-type 5-
HT2C receptor (left two bars), insulin treatment resulted in 
a significant reduction of the peak Cl- current in response to 
5-HT.  In cells expressing the MAP kinase site mutation 
S159A (right two bars), insulin had no effect on the 5-HT-
activated Cl- current.  The data are presented as the mean ± 
S.E.M. of 6 oocytes (*, P < 0.05).Page 5 of 9
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HT2C receptor are unknown but these reports suggest
finely tuned control of 5-HT2C receptor function and
density.
Several studies have utilized heterologous expression sys-
tems to identify mechanisms of 5-HT2C receptor regula-
tion. Phosphorylation most likely has a prominent role in
regulation of the 5-HT2C receptor. Westphal and col-
leagues [31] demonstrated that the 5-HT2C receptor
exhibits basal phosphorylation, and that agonist treat-
ment was associated with increased phosphorylation and
receptor desensitization in transfected cells. The expressed
5-HT2C receptor exhibits homologous and heterologous
desensitization in oocytes [32] mediated by protein
kinase C [33–35]. A calmodulin-dependent kinase may
also be involved in homologous desensitization [36]. In
contrast, a recent study indicates that neither PKC nor cal-
modulin-dependent protein kinase II are involved,
instead desensitization of the 5-HT2C receptor is depend-
ent on GRK activity [37]. Interestingly, tyrosine kinase
involvement in the agonist-mediated phosphorylation of
the rat 5-HT2C receptor has also been reported [38],
although as yet no report has shown that the 5-HT2C
receptor directly activates tyrosine kinases.
The 5-HT2C receptors are subject to another form of regu-
lation by means of mRNA editing [39]. RNA editing [40]
is a type of posttranscriptional modification that occurs
when double-stranded RNA deaminase converts genomi-
cally coded adenosines to inosines, thereby changing the
coding sequence of specific RNA transcripts. RNA editing
of the rat 5-HT2C receptor was first described by Burns et
al. [39] and editing at four nucleotide sites alters three
amino acids within the second intracellular loop. RNA
editing of the 5-HT2C receptor is conserved among species
[41] and at least 7 major isoforms with tissue-specific
expression patterns have been described in rat brain [39]
suggesting a functional importance. The mouse cDNA
clone used in our study codes for the fully edited form
(Val157-Ser159-Val161) of the receptor. The putative
MAP kinase site (Ser159) we identified and mutated in
this study is also a site of mRNA editing in this receptor;
i.e. Ser159 is only present in edited forms. The fully edited
rat 5-HT2C receptor exhibits reduced agonist efficacy or
ability to interact with G proteins compared to the
unedited receptor (Ile157-Asn159-Ile161) in transfected
cells [39]. Interestingly, 5-HT elicits a larger response (see
Fig. 4c) in cells expressing the mutant receptor (S159A)
compared to the fully edited mouse receptor, and the
mutant receptor is not regulated by insulin. Binding of
radiolabelled mesulergine was similar in the edited 5-
HT2C and S159A mutant receptors in transfected cells
(data not shown). These results suggest some intriguing
possibilities. Either the mutant receptor (S159A) couples
more readily to G proteins compared to the fully edited 5-
HT2C receptor, or the edited (Ser159 containing) receptor
may be phosphorylated to some extent in the basal state.
We hypothesize that the phosphorylated receptor may
couple less efficiently to G proteins, but this hypothesis
remain to be tested. Our results indirectly suggest that 5-
HT2C receptors containing Ser159 may be subject to yet
another form of regulation; i.e., phosphorylation by MAP
kinase.
The 5-HT2C receptor is very abundant in choroid plexus
[8,42], and is the only 5-HT receptor present on these
cells. Choroid plexus cells line the cerebral ventricles,
form the blood-CSF barrier, and are responsible for the
production of cerebrospinal fluid (CSF) [43]. Although
the mechanisms have not been delineated, the 5-HT2C
receptor is thought to regulate CSF production and the
expression of transferrin. For example, upon intraven-
tricular injection, 5-HT2C agonists decrease the production
of CSF [44] and in primary cultures of choroid plexus, 5-
HT agonists increase the expression of transferrin [45,46],
an iron carrier protein which has trophic effects on the
brain. In addition, choroid plexus expresses insulin, IGF-
I, and IGF-II receptors [11,47]., as well as large amounts of
IGF-II that is secreted into the CSF [47]. CSF contains
insulin/IGFs and 5-HT [48] in concentrations high
enough to activate their respective receptors in choroid
plexus, suggesting that this signaling mechanism may
occur in vivo. It has been suggested that 5-5HT2C receptors
in choroid plexus may be tonically activated, due to CSF
5-HT concentrations near the EC50, thus tonically inhibit-
ing CSF production. Our data suggest that insulin may
reduce 5-HT2C receptor activity, thereby increasing CSF
production and decreasing transferrin production. As a
consequence, insulin inhibition of 5-HT2C receptor activ-
ity may change the volume and composition of CSF and
indirectly may alter the concentrations of many poten-
tially important signaling molecules in CSF.
MAP kinase regulation is potentially an important mech-
anism of modulating GPCR function, however the preva-
lence of this type of modulation is unknown. Our results
suggest that the 5-HT2C receptor is a MAP kinase substrate,
whereas the M1 Ach receptor is not. The optimal
consensus site for MAP kinase phosphorylation isPro-X-
(Ser/Thr)-Pro, however in some cases the upstream Pro is
not required and a minimal sequence of Ser-Pro or Thr-
Pro is phosphorylated (for review, see Davis, 1993[21]).
The 5-HT2C receptor site is just such a minimal sequence
of Ser-Pro and it is the only MAP kinase site we identified
within the receptor's presumed intracellular domains.
This site is not conserved within the M1 Ach receptor or
other 5-HT2 type receptors. Although all of these receptors
contain Ser-Pro or Thr-Pro sequences within intracellular
domains it is difficult to determine the importance ofPage 6 of 9
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not inhibit Ach receptor signaling in our experiment, the
rat M1 Ach receptor contains several MAP kinase sites,
including one Thr-Pro sequence in the 2nd intracellular
loop and 3 Ser-Pro and one Thr-Pro in the 3rd intracellular
loop. The reason for this apparent discrepancy is unclear
but may be related to a "spare receptor" phenomenon in
the oocyte expression system. Alternatively, additional
sequence or regulatory elements, which have not been
identified, may be required for MAP kinase phosphoryla-
tion. Determining the prevalence and specificity of MAP
kinase modulation of GPCR's will await future studies.
Conclusions
Taken together, our results demonstrate that insulin/IGF-
1 signaling down-regulates 5-HT2C receptor function in
choroid plexus and Xenopus oocytes via MAP kinase, and
that the 5-HT2C receptor is a substrate for MAP kinase. To
our knowledge, this is the first description of MAP kinase
regulation of a GPCR and suggests that this form of regu-
lation may be more wide-spread than has been previously
recognized. Furthermore, since some GPCRs can modu-
late MAP kinase activity, MAP kinase regulation of GPCR
function may then serve as a form of negative feedback
control in much the same way that protein kinase A,
protein kinase C and the G protein-coupled receptor
kinases (GRKs) regulate GPCRs.
Methods
Chemicals and Reagents
Cell culture reagents and enzymes including MEM, HAM's
F12, D-valine, dialyzed fetal calf serum, Pronase and
DNase I are from Life Technologies (Grand Island, NY)
except as noted. All other chemicals are from Sigma (St.
Louis, MO) except as noted. PD 098059 was kindly pro-
vided by Dr. A. R. Saltiel (Parke-Davis Pharmaceutical
Research, Ann Arbor, Michigan). Purified ERK2 was
kindly provided by Dr. M. H. Cobb (Department of Phar-
macology, UT Southwestern Medical Center, Dallas, TX).
Choroid plexus cell isolation and culture
All animal experiments in this work have been carried out
in accordance with the Guide for the Care and Use of Lab-
oratory Animals as required by the U.S. National Insti-
tutes of Health. Choroid plexus cells were isolated as
described [46]. Briefly, choroid plexus from adult male
Sprague-Dawley rats (175-200 g) were dissected into cold
Locke's buffer, rinsed and enzymatically dissociated for 10
minutes at 37° C in Hank's Balanced Salt Solution (HBSS)
containing 330 ug/ml Pronase I and 260 ug/ml DNase I.
The cells were pelleted and choroid plexus cells were
released after an additional digest with 130 ug/ ml DNase
I in HBSS. The cells were resuspended in MEM containing
D-valine and 15% dialyzed fetal calf serum and plated on
concavalin A-coated round glass coverslips. Four days
later the media was replaced with Ham's F12 medium.
Intracellular calcium measurements
After 7 days in culture, cells were loaded with 1.5 µM fura-
2 AM (Molecular Probes, Eugene, OR) in HBSS and 1 mg/
ml bovine serum albumin (BSA) for 30 minutes at 22°C
and washed in HBSS for 30 minutes at 22°C. Cells were
continuously superperfused with HBSS containing the
indicated drugs. Insulin (10 or 20 µM) was diluted into
HBSS containing 1 mg/ml BSA, and 5-HT (2 uM) was
diluted into HBSS. Some cells were pretreated with 50 µM
PD 098059 for 30 minutes before intracellular calcium
measurements. Fura imaging was done using software
kindly provided by Dr. Eric Gruenstein of University of
Cincinnati and was carried out as previously described
[49]. Peak intracellular calcium responses were measured
from individual cells and pooled for statistical analysis.
Oocyte injection and drug treatment
Oocytes were injected with in vitro transcribed RNA for the
mouse 5-HT2C [50] and the M1 acetylcholine (kindly pro-
vided by Dr. T. Bonner) receptors for the experiment in
Fig. 2 or the 5-HT2C receptor alone for all other experi-
ments. Three days after RNA injection, oocytes were stim-
ulated with 5-HT or Ach, and the chloride current was
measured using a two-electrode voltage-clamp
(Axoclamp-2A, Axon Instruments, Foster City, CA).
Oocytes were subjected to different treatments as follows.
For insulin or IGF-1 treatment, oocytes were treated with
1 µM insulin or 100 nM IGF-1 in ND96 (96 mM NaCl, 2
mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.6) and 1 mg/
ml BSA for 5 minutes, then rinsed in ND96 for 2 minutes
before stimulation with 1 µM 5-HT or 10 µM Ach. For the
experiments in Fig. 3, some oocytes were pretreated with
1 µM genistein for 60 minutes or were injected with RAS
antibody (0.65 µg/50 nl) 5 minutes before 5-HT stimula-
tion or treatment with IGF-1 followed by 5-HT stimula-
tion. For the experiments in Fig. 4a, some oocytes were
pretreated with either PD 098059 [19] (50 µM for 30 min-
utes) or protein kinase C inhibitor, myristoylated EGF-R
(Calbiochem, La Jolla, CA), (5 µM for 30 minutes) before
5-HT stimulation or treatment with IGF-1 followed by
stimulation with 5-HT. In Fig. 4b, some oocytes were
injected with active MAP kinase (ERK2, 10 ng/cell) or
MAP kinase buffer 5 minutes before 5-HT stimulation or
treatment with IGF-1 followed by stimulation with 5-HT.
For Fig. 4c, oocytes were injected with in vitro transcribed
RNA for the 5-HT2C receptor or the 5-HT2C S149A mutant
receptor. The oocytes were stimulated with 5-HT or
treated with insulin followed by stimulation with 5-HT.
Site-directed mutagenesis
The putative MAP kinase site on the 5-HT2C receptor, ser-
ine 159, was mutated to alanine by PCR with primers con-Page 7 of 9
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PCR product was subcloned into the same vector as the
wild-type 5-HT2C receptor, and the mutation confirmed
by DNA sequencing.
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